for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shanghai Fosun Pharmaceutical (Group)

600196.SS

Latest Trade

58.99CNY

Change

1.48(+2.57%)

Volume

30,106,585

Today's Range

56.64

 - 

59.42

52 Week Range

36.67

 - 

91.69

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Shanghai Fosun Pharmaceutical's H1 Net Profit Up 44.8% Y/Y

Aug 23 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK ::SAYS H1 NET PROFIT UP 44.8% Y/Y.

Shanghai Fosun Pharma Sells 25% Stake In Tianjin Tianyao's Controlling Shareholder

Aug 23 (Reuters) - Tianjin Tianyao Pharmaceuticals Co Ltd <600488.SS>::SAYS SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD <<<600196.SS>>> IN DEAL TO SELL ITS 25% STAKE IN CO'S CONTROLLING SHAREHOLDER FOR 1.4 BILLION YUAN ($215.77 million).

Shanghai Fosun Pharma's Unit Agrees To Pay 230 Mln Yuan To Obtain Stake In Abcarta

Aug 20 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS DIAGNOSTIC UNIT AGREES TO PAY 230 MILLION YUAN ($35.40 million) TO OBTAIN STAKE IN ABCARTA.SAYS DIAGNOSTIC UNIT'S STAKE IN ABCARTA WILL RISE TO 58.7% AFTER THE TRANSACTION.

Shanghai Fosun Pharma Says Unit Got Approval for Clinical Trial regarding Investigational New Drug

Aug 9 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::UNIT RECENTLY GOT APPROVAL FROM NMPA OF CONSENT TO COMMENCE CLINICAL TRIAL OF FH-2001 CAPSULES.

Fosun Pharma's Unit Plans To Participate In Privatisation Of New Frontier Health Corp

Aug 4 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::SAYS ITS UNIT PLANS TO PARTICIPATE IN PRIVATISATION OF NEW FRONTIER HEALTH CORP.

Kintor Pharma Says Unit Entered Proxalutamide Licensing Agreement

July 15 (Reuters) - Kintor Pharmaceutical Ltd <9939.HK>::UNIT ENTERED PROXALUTAMIDE LICENSING AGREEMENT WITH SHANGHAI FOSUN PHARMACEUTICAL DEVELOPMENT.FOSUN PHARMA DEVELOPMENT WILL BE GRANTED EXCLUSIVE RIGHTS OF REGISTRATION AND COMMERCIALISATION OF PROXALUTAMIDE IN COLLABORATION REGIONS.WILL BE ELIGIBLE TO RECEIVE UPFRONT AND MILESTONE PAYMENTS UP TO RMB560 MILLION.CO WILL ALSO BE ELIGIBLE TO RECEIVE ROYALTY PAYMENTS THAT ARE NOT LESS THAN 50% OF TOTAL OPERATING PROFIT IN COLLABORATION REGIONS.KINTOR PHARMACEUTICAL COLLABORATES WITH FOSUN PHARMA DEVELOPMENT TO COMMERCIALISE PROXALUTAMIDE FOR TREATMENT OF COVID-19 IN INDIA AND AFRICA.

JPMorgan Chase & Co's Long Position In Shanghai Fosun Pharma Falls To 4.69% - HKEX Filing

June 28 (Reuters) - Hong Kong stock exchange filing::PMORGAN CHASE & CO'S LONG POSITION IN SHANGHAI FOSUN PHARMA 2196.HK REDUCED TO 4.69% ON JUNE 23 FROM 5.56% - HKEX FILING.

Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA

June 23 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::UNIT RECEIVED MARKETING REGISTRATION APPROVAL FROM NMPA FOR AUTOLOGOUS CD19-DIRECTED CAR-T CELL THERAPY AXICABTAGENE CILOLEUCEL.Further company coverage: 600196.SS. ((Reuters.Briefs@thomsonreuters.com;)).

JPMorgan Chase & Co's Long Position In Shanghai Fosun Pharma Rises To 5.09% - HKEX Filing

June 15 (Reuters) - Hong Kong stock exchange filing::JPMORGAN CHASE & CO'S LONG POSITION IN SHANGHAI FOSUN PHARMACEUTICAL 2196.HK INCREASED TO 5.09% ON JUNE 10 FROM 4.59% - HKEX FILING.

Shanghai Fosun Pharmaceutical Group Says Got NMPA Approval For An Investigational New Drug

June 11 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::UNIT GETS APPROVAL FOR IND FROM NMPA FOR AUTOLOGOUS CD19-DIRECTED CAR-T CELL THERAPY.Further company coverage: 600196.SS. (Reuters.Briefs@thomsonreuters.com).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up